Study to Compare the Efficacy and Safety of DenosumAb Versus Placebo in Males With Osteoporosis

NCT00980174 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

242

Enrollment

INDUSTRY

Sponsor class

Conditions

Low Bone Mass
Low Bone Mineral Density
Males With Osteoporosis
Osteopenia
Osteoporosis

Interventions

DRUG: 60 mg denosumab
OTHER: Placebo

Sponsor

Amgen